Treatment and Response to Induction Chemotherapy: All patients were given standard "3+7" induction chemotherapy with daunorubicin (45mg/m2)and cytarabine (100 mg/m2) followed by consolidation therapy with high dose cytosine
arabinoside (3g/m2 12hrly on day 1, 3 and 5).
Pre-transplant risk factors of SOS include liver dysfunction (hepatitis, fibrosis, cirrhosis, etc.), hepatic metastases, history of liver radiotherapy, hepatotoxic agents (including herbal remedies, gemtuzumab ozogamicin, melphalan, cytosine
arabinoside, and cyclophosphamide), infectious attacks, iron overload, history of stem cell transplantation, and advanced age.
"Cytosine
Arabinoside with Daunorubicin or Adriamycin for Therapy of Acute Myelocytic Leukemia: A CALGB Study." Blood 60 (2): 454-62.
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine
arabinoside. Blood 2002; 99: 4343-9.
Her ALL was treated with protocol CCG 1961, consisting of vincristine, cytosine
arabinoside, pegylated-asparaginase, doxorubicin, methotrexate, and cyclophosphamide.
All patients received hydrocortisone, cytosine
arabinoside and methotrexate intrathecally for CNS prophylaxis with no irradiation.
The incidence of cerebellar toxicity with high-dose
arabinoside cytarabine (HIDAC) is ~ 10%.[4] It can be diagnosed in a way that the MRI brain reveals cerebellar atrophy and reversible white matter changes.
The patient underwent treatment with DDAVP for central diabetes and systemic chemotherapy consisting of (I) vinblastine (VBL; 8 mg/day, intravenous infusion) and prednisolone (PSL; 30 mg/day, intravenous infusion) on Day 1 and (II) cytosine
arabinoside (AraC; 200 mg/day, intravenous infusion) and PSL (30 mg/day, intravenous infusion) on Day 2 every 4 weeks.